2023 Baystate Webinar Series
June 6-8 and 12-15, 2023 | 2:00 pm -3:00 pm ESTJoin us for the virtual Baystate Webinar Series and earn live CE credit. There will be seven sessions over two weeks. You will need to register for each webinar that you wish to attend separately.
Registration for each session is complimentary for all. Advance registration is required for individual sessions. You will receive a registration confirmation email once you register. Registered individuals will receive a personalized access link from Zoom one day before and one hour before the webinar. Registration for each session will close one day before the webinar.
Register on the MCPHS CE Portal.
Each live webinar will be hosted on Zoom Webinar. Audience cameras and audio will be disabled. The presentations are pre-recorded to assure audio quality and connectivity, but the presenters will be present to pose engagement questions and answer inquiries throughout and after the session via the webinar Q&A function. Please contact continuing.education@mcphs.edu with any technical access questions.
The sessions will be available as on-demand modules for home study credit later in the month.
June 6-8 Live Webinars
June 6, 2023 — 2:00-3:00 PM EST
Although human immunodeficiency virus (HIV) is a global health problem, pharmacists may be unfamiliar with principles of antiretroviral therapy due to its complexity and relatively infrequent use when compared to other common disease treatments. With transformative new developments in clinical practice, pharmacists must understand how to implement these recommendations that have been shown to reduce morbidity, mortality, and disease transmission. This presentation will provide an overview of pharmacotherapy for the prevention of HIV, and present important considerations for selecting an initial regimen for newly diagnosed patients.
At the completion of this activity, the participant should be able to:
- Describe the history of HIV treatment and recent significant advances in pharmacotherapy for HIV.
- Recognize workplace-specific clinical practices, protocols, and resources for the prevention, diagnosis, and treatment initiation of HIV
- Recall important clinical pearls for preventing, selecting, and initiating treatment regimens for HIV.
Presenter: Erin Persico, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center. She graduated from the University of Rhode Island College of Pharmacy with her PharmD in 2022. Her clinical interests include internal medicine, emergency medicine, and oncology.
Activity Number: 0026-0000-23-010-L02-P | Knowledge-based
Topic Designator: HIV/AIDS Therapy
Contact Hours: 1.0
June 7, 2023 — 2:00-3:00 PM EST
While spontaneous intracerebral hemorrhage (sICH) is not as common as ischemic stroke, prompt diagnosis and management of sICH is essential to improve patient outcomes. The American Heart Association released new guidelines in 2022 for the management of this condition. Referring to these updates, the session will provide pharmacists with updated, evidence-based recommendations to improve practice and patient care in those with sICH. This presentation will cover background information on sICH, blood pressure control, anticoagulant reversal, and the types of supportive care required for these patients.
At the completion of this activity, the participant should be able to:
- Review the pathophysiology, presentation, and diagnosis of spontaneous intracerebral hemorrhage (sICH)
- Explain guideline recommended management of blood pressure and anticoagulant reversal in patients with sICH
- Describe supportive care measures in patients with sICH
- Identify secondary prevention measures in patients with sICH
Presenter: Emily Duff, PharmD, is a PGY2 Critical Care Pharmacy Resident at Baystate Medical Center. She earned her PharmD from the University of Rhode Island in 2021. Her primary interest areas include medical intensive care, emergency medicine, and academia.
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0
June 8, 2023 — 2:00-3:00 PM EST
Kawasaki Disease is a medium vessel vasculitis that typically presents as an acute, self-limited febrile disease. Prompt diagnosis and treatment lead to improved cardiac outcomes for patients. This session will review background information and updated guidelines and recommendations from the American College of Rheumatology and Vasculitis Foundation for the treatment of Kawasaki disease, enabling pharmacists to actively participate in patient care discussions.
At the completion of this activity, the participant should be able to:
- Explain the pathophysiology and diagnosis of Kawasaki Disease
- Provide evidence-based treatment recommendations for patients initially presenting with Kawasaki Disease
- Evaluate the treatment approaches for complex and refractory cases of Kawasaki Disease
Presenter: Anne Balogh, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center. She earned her PharmD at the University of Michigan College of Pharmacy in 2022. Her practice interests include pediatrics and emergency medicine.
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0
June 12-15 Webinar Schedule
June 12, 2023 — 2:00-3:00 PM EST
Current practice indicates that COVID-19 and pneumococcal vaccines be used to optimize patient outcomes and protect the community through herd immunity. This session will provide a detailed overview of updated guidelines related to COVID-19 and pneumococcal vaccines. Additionally, the presentation will offer professionals guidance on determining patients' vaccine eligibility and addressing instances of vaccine hesitance.
At the completion of this activity, the participant should be able to:
- Describe new CDC guidance on vaccination recommendations for COVID-19 and pneumococcal vaccines
- Review the different types of COVID-19 and pneumococcal vaccines and emergency management for related
adverse reactions - Evaluate clinical considerations for special populations
Presenter: Ashley Iacoviello, PharmD, RPh, is a PGY1/2 Health System Pharmacy Leadership & Administration Resident at Baystate Medical Center. She received her PharmD from Massachusetts College of Pharmacy and Health Sciences in 2021. Some of her professional interests include pharmacy leadership and administration, immunizations, and informatics.
Register for the Webinar
Activity Number: 0026-0000-23-014-L06-P| Knowledge-based
Topic Designator: Immunizations
Contact Hours: 1.0
June 13, 2023 — 2:00-3:00 PM EST
The American College of Chest Physicians released a clinical practice executive summary on the perioperative management of antithrombotic therapy in August 2022. This session will review the summary, including 43 recommendations that have been changed from the 2012 iteration of the guidelines. The presentation will get providers up-to-date so that their workplace practices are based off the most recent evidence-based updates.
At the completion of this activity, the participant should be able to:
- Describe the mechanism of action, monitoring, and side effects of all current antithrombotic medications addressed in the CHEST guidelines
- Classify risk of peri-procedural thromboembolism/procedural bleeding for patients based on specific characteristics
- Discuss guideline recommended options for the timing of interruption/resumption for each anticoagulant
Presenter: Clara Forbes, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center. She received her PharmD from the University of Rhode Island in 2022. Her professional interests include emergency medicine and pediatrics.
Activity Number: 0026-0000-23-015-L01-P| Knowledge-based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0
June 14, 2023 — 2:00-3:00 PM EST
Gaps in pharmacist knowledge about the management of penicillin and cephalosporin allergies can compromise patient care. Furthermore, many patients are unnecessarily diagnosed with allergies to these medications, leaving them treated with less effective antibiotics and improper antimicrobial coverage. This session will address best pharmacy practices for treating patients with allergies, flagging cross-reactivities, and de-labeling patients that have been inappropriately diagnosed with allergies to these antibiotics.
At the completion of this activity, the participant should be able to:
- Describe the risks associated with allergy mislabeling
- Assess the cross-reactivities between beta-lactams
- Identify appropriate administration strategies for patients with documented penicillin and cephalosporin allergies
- Define strategies to de-label inappropriate allergies
Presenter: Briana O'Connell, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center. She received her PharmD from Western New England University in 2022. Her professional interests include critical care and emergency medicine.
Activity Number: 0026-0000-23-016-L01-P| Knowledge-based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0
June 15, 2023 — 2:00-3:00 PM EST
Acetaminophen toxicity can occur due to acute ingestion or chronic excessive dosage. The progression of toxicity is categorized and patients' clinical presentation may vary depending on time from ingestion. Pharmacists will utilize the content of this presentation to recognize the state and make informed treatment decisions when confronted with a patient demonstrating acetaminophen toxicity. This session will emphasize the best practice methods and key points from primary literature on treating acetaminophen toxicity.
At the completion of this activity, the participant should be able to:
- Explain the pharmacokinetics and pathophysiology of acetaminophen toxicity
- Discuss the principles of treatment for acetaminophen toxicity
- Describe key points published within current literature to support recommendations for antidote therapy
- Construct a treatment plan for management of a patient presenting with an acute acetaminophen ingestion
Presenter: Jennifer Hammond, PharmD, is a PGY2 Emergency Medicine Pharmacy Resident at Baystate Medical Center. She received her PharmD from the University of New England School of Pharmacy in 2021. Her professional interests include critical care and emergency medicine
Activity Number: 0026-0000-23-013-L01-P | Knowledge-based
Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0
Accreditation
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 1 contact hours (0.1 CEU) per session.
In order to receive credit, the participant must be present the entirety of each presentation and complete the pre and post-tests, and evaluation form for each session. Attendance will be verified. Upon completion of the evaluation, participant credit will be reported to CPE Monitor. Transcripts may be printed from the CPE Monitor.
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Disclosures
Erin Persico, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Emily Duff, PharmD, has no relevant financial relationships with ineligible companies to disclose. She will discuss off-label usage of 4-factor prothrombin complex concentrate, protamine, desmopressin, recombinant factor VIIa, and tranexamic acid.
Anne Balogh, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Ashley Iacoviello, PharmD, RPh, has no relevant financial relationships with ineligible companies to disclose.
Clara Forbes, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Briana O'Connell, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Jennifer Hammond, PharmD, has no relevant financial relationships with ineligible companies to disclose. She will discuss the off-label/investigational usage of fomepizole and intravenous acetylcysteine in the setting of acetaminophen toxicity.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event.